{"id":"W2128542677","doi":"10.1056/nejmoa1103782","title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7688,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Vemurafenib; Medicine; Dacarbazine; Interim analysis; Internal medicine; Adverse effect; Melanoma; Oncology; Rash; Dabrafenib; Progression-free survival; Nausea; Clinical trial; Cancer research; Metastatic melanoma; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008445873,0.0002372165,0.0004498042,0.000178215,0.0001014512,0.000221148,0.0001882189,0.0001800431,0.00123204],"category_scores_gemma":[0.0009019055,0.00006918138,0.0004808526,0.0001213748,0.0001956896,0.0001876891,0.0002103459,0.0004963441,0.0001206485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002341401,"about_ca_system_score_gemma":0.0002332619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001835926,"about_ca_topic_score_gemma":0.0004021598,"domain_scores_codex":[0.9997167,0.0001430699,0.00001486479,0.0000368608,0.00003864832,0.00004982441],"domain_scores_gemma":[0.9997339,0.00009326206,0.0000810057,0.00001625118,0.00001228661,0.00006329297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.242574,0.01000532,0.08966987,0.001113135,0.00153538,0.0008762745,0.0002969125,0.009980792,0.09372028,0.0003682655,0.002228821,0.547631],"study_design_scores_gemma":[0.04944564,0.3887821,0.5095587,0.0001930126,0.001711291,0.004420728,0.0001552954,0.008731132,0.02496947,0.001350382,0.01062291,0.00005916296],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970224,0.002013559,0.0004095958,0.00009229236,0.00001906105,0.00002770818,0.00005398614,0.00001706524,0.0003443662],"genre_scores_gemma":[0.9988675,0.0005498672,0.0002366564,0.00005676489,0.00002564824,0.00002587409,0.0001219832,0.00000207731,0.0001137537],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00123204,"threshold_uncertainty_score":0.004466653,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0159994996001733,"score_gpt":0.22066546399615,"score_spread":0.2046659643959767,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}